Company intelligence / Profile preview
Orphalan
Paris, Île-de-France, Franceorphalan.com ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Commercial
01
Overview
Orphalan has successfully developed and commercialized trientine tetrahydrochloride as a treatment for Wilson disease. The drug has been approved in over 20 countries under various brand names. Clinical data from the pivotal Phase 3 CHELATE trial supported regulatory approvals. The company continues to innovate with new formulations to improve adherence and patient outcomes, as well as developing novel assays to measure treatment effectiveness.
Adherence challenges remain a key area of research focus.
Expansion into China marks significant global reach.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecules (notably trientine tetrahydrochloride for Wilson disease)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SPH Kyuan Trade Co., Ltd. (for commercialization/distribution in China)
Beyond the preview
Go deeper on Orphalan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orphalan.